The Denver Network of the NHLBI Progenitor Cell Biology Consortium

描述（由申请人提供）：本申请建议建立NHLBI祖细胞生物学联盟的丹佛网络。RFA的时间与丹佛新的多机构干细胞计划完全吻合。一个新的再生医学和干细胞生物学计划（RMSCBP）于2007年在科罗拉多大学丹佛分校（UCD）成立，这导致了7名新教师的招聘，他们的研究工作集中在干细胞生物学上。为了配合这一倡议，国家犹太健康（NJH）招募了两名杰出的肺干细胞生物学家。这些新员工加入了24个现有的教师，形成了一个多机构，全面的干细胞计划，包括30多个主要成员谁拥有以折扣价获得国家的最先进的核心设施（http：//www.uchsc.edu/stemcell/）。本申请中提出的项目是由于这些新的干细胞倡议而在去年启动的现有合作的优秀例子。具体而言，本申请提出利用Denver Network在造血和皮肤干细胞生物学领域的现有专业知识来产生改进的试剂以鉴定和表征肺和血管祖细胞谱系。此外，为了促进分离肺和血管干细胞和祖细胞的新方法的开发，并指导这些细胞分化为所需的细胞命运，我们建议建立新的核心设施，利用丹佛网络成员开发的新技术。最后，将探索通过新型非病毒方法产生的条件永生化长期造血干细胞和诱导多能干细胞（iPS）用于治疗血液和肺部疾病的治疗潜力。该应用程序的翻译和临床方面，以及拟议的指导和培训计划，将大大促进由科罗拉多临床转化科学研究所（CCTSI）。临床和翻译科学，研究和培训在UCD及其六个附属机构，其中包括NJH，最近成功地整合到CCTSI后，收到了7600万美元的CTSA奖。

DESCRIPTION (provided by applicant): This application proposes to establish the Denver Network of the NHLBI Progenitor Cell Biology Consortium. The timing of this RFA coincides perfectly with new a multi-institutional stem cell initiative in Denver. A new Regenerative Medicine and Stem Cell Biology Program (RMSCBP) was established at the University of Colorado Denver (UCD) in 2007, which has resulted in the recruitment of 7 new faculty whose research efforts focus on stem cell biology. In concert with this initiative, National Jewish Health (NJH) recruited two outstanding lung stem cell biologists. These new recruits have joined 24 existing faculty to form a multi-institutional, comprehensive stem cell program consisting of over 30 primary members who have access to state-of-the-art Core Facilities at discounted rates (http://www.uchsc.edu/stemcell/). The projects proposed in this application are excellent examples of existing collaborations that were initiated within the last year as a result of these new stem cell initiatives. Specifically, this application proposes to utilize the existing expertise within the Denver Network in the areas of hematopoietic and skin stem cell biology to generate improved reagents to identify and characterize lung and vascular progenitor cell lineages. In addition, to facilitate the development of new methods for isolating lung and vascular stem and progenitor cells, and for directing the differentiation of these cells to desired cell fates, we propose to establish new Core Facilities which utilize novel technologies developed by members of the Denver Network. Finally, the therapeutic potential of conditionally immortalized long-term hematopoietic stem cells and induced pluripotent stem (iPS) cells, which will be generated by novel non-viral methods, will be explored for the treatment of hematological and lung disorders. The translational and clinical aspects of this application, as well as the proposed mentoring and training program, will be greatly facilitated by the Colorado Clinical Translational Science Institute (CCTSI). The clinical and translation sciences, research, and training at UCD and its six Affiliates, which includes NJH, were recently successfully integrated into the CCTSI following the receipt of a CTSA award of $76 million.